MX2019010045A - Metodos para determinar la potencia de preparaciones de virus adeno-asociados. - Google Patents

Metodos para determinar la potencia de preparaciones de virus adeno-asociados.

Info

Publication number
MX2019010045A
MX2019010045A MX2019010045A MX2019010045A MX2019010045A MX 2019010045 A MX2019010045 A MX 2019010045A MX 2019010045 A MX2019010045 A MX 2019010045A MX 2019010045 A MX2019010045 A MX 2019010045A MX 2019010045 A MX2019010045 A MX 2019010045A
Authority
MX
Mexico
Prior art keywords
methods
adeno
associated virus
virus preparations
preparations
Prior art date
Application number
MX2019010045A
Other languages
English (en)
Inventor
Necina Roman
Fiedler Christian
Bendik Marian
Boehm Ernst
Graninger Michael
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2019010045A publication Critical patent/MX2019010045A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/36—Embedding or analogous mounting of samples
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/42—Low-temperature sample treatment, e.g. cryofixation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/015—Parvoviridae, e.g. feline panleukopenia virus, human Parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Optics & Photonics (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En este documento se proporcionan métodos para medir los atributos cualitativos y/o cuantitativos de preparaciones de vectores de terapia génica. En ciertas modalidades, las preparaciones de vectores de terapia génica son preparaciones de virus adeno-asociados (AAV) (por ejemplo, AAV8). En ciertas modalidades, los métodos comprenden determinar la potencia o dosis de la preparación de AAV usando un ensayo ELISA, o un ensayo ELISA en combinación con la microscopía electrónica por transmisión criogénica (CryoTEM).
MX2019010045A 2017-03-03 2018-03-02 Metodos para determinar la potencia de preparaciones de virus adeno-asociados. MX2019010045A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762467045P 2017-03-03 2017-03-03
PCT/US2018/020676 WO2018160975A1 (en) 2017-03-03 2018-03-02 Methods for determining potency of adeno-associated virus preparations

Publications (1)

Publication Number Publication Date
MX2019010045A true MX2019010045A (es) 2019-10-02

Family

ID=61692094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010045A MX2019010045A (es) 2017-03-03 2018-03-02 Metodos para determinar la potencia de preparaciones de virus adeno-asociados.

Country Status (12)

Country Link
US (1) US20200018752A1 (es)
EP (1) EP3589956A1 (es)
JP (1) JP7232766B2 (es)
KR (1) KR102590519B1 (es)
CN (1) CN110352353B (es)
AU (1) AU2018227883B2 (es)
BR (1) BR112019018216A2 (es)
CA (1) CA3053176A1 (es)
IL (1) IL268600A (es)
MX (1) MX2019010045A (es)
SG (1) SG11201908055WA (es)
WO (1) WO2018160975A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021153659A1 (ja) * 2020-01-31 2021-08-05 Ａｇｃ株式会社 アデノ随伴ウイルス（ａａｖ）の定量方法
CN113552349B (zh) * 2021-07-30 2022-07-19 上海勉亦生物科技有限公司 Aav蛋白外壳的检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030149235A1 (en) * 2000-11-17 2003-08-07 Baker Andrew Howard Targeting peptides
US20100239609A1 (en) 2007-05-04 2010-09-23 Baxter International Inc. Formulation of Sugar Solutions for Continuous Ultracentrifugation for Virus Purification
US8906863B2 (en) * 2009-02-27 2014-12-09 The Regents Of The University Of California Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector
JP5763631B2 (ja) * 2009-07-01 2015-08-12 コーニンクレッカ フィリップス エヌ ヴェ Ｍｐｉ誘導による薬物送達のための刺激応答性キャリア
GB0913433D0 (en) * 2009-07-31 2009-09-16 Isis Innovation Method
AU2013202339A1 (en) * 2010-03-19 2013-05-02 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
WO2013016498A1 (en) * 2011-07-26 2013-01-31 Nanoimaging Services Characterization of particulates using electron microscopy and image processing methods
EP2771455B1 (en) * 2011-10-28 2016-10-05 The University of North Carolina At Chapel Hill Cell line for production of adeno-associated virus
EP2963646A1 (en) * 2014-07-01 2016-01-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Decoder and method for decoding an audio signal, encoder and method for encoding an audio signal
EP3313987B1 (en) * 2015-06-23 2019-10-23 Deutsches Krebsforschungszentrum Method for large scale production and purification of parvovirus

Also Published As

Publication number Publication date
WO2018160975A1 (en) 2018-09-07
AU2018227883B2 (en) 2022-08-04
EP3589956A1 (en) 2020-01-08
BR112019018216A2 (pt) 2020-06-23
RU2019127780A3 (es) 2021-12-22
JP2020511630A (ja) 2020-04-16
CN110352353B (zh) 2023-12-15
KR20190122245A (ko) 2019-10-29
CA3053176A1 (en) 2018-09-07
JP7232766B2 (ja) 2023-03-03
RU2019127780A (ru) 2021-04-05
US20200018752A1 (en) 2020-01-16
SG11201908055WA (en) 2019-09-27
AU2018227883A1 (en) 2019-08-29
IL268600A (en) 2019-09-26
CN110352353A (zh) 2019-10-18
KR102590519B1 (ko) 2023-10-17

Similar Documents

Publication Publication Date Title
MX2021006646A (es) Vector viral adenoasociado recombinante para el suministro de genes.
AU2018260998A1 (en) Modulatory polynucleotides
MX2024008677A (es) Conjugados de camptotecina.
PH12018500594A1 (en) Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
WO2018119330A3 (en) Adeno associated viral vectors
BR112018071167A2 (pt) entrega de beta-sarcoglicano e microrna-29 por vírus adenoassociado e tratamento de distrofia muscular
WO2018191750A3 (en) Novel delivery of large payloads
EP4303225A3 (en) Polyploid adeno-associated virus vectors and methods of making and using the same
MX2021012014A (es) Vectores del factor viii del virus adeno-asociado.
PH12020551716A1 (en) Anti-ror antibody constructs
MX2023013435A (es) Composiciones y metodos para expresar otoferlina.
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
MX2017011615A (es) Construcciones de vectores virales adeno-asociados de glut1 recombinantes y métodos relacionados para restablecer la expresión de glut1.
MY195465A (en) PD-L1 Antibody Pharmaceutical Composition and use Thereof
SA520420518B1 (ar) تبديل الانتحاء النسيجي للفَيروسات المُرتَبِط بالفَيروس الغُدِّيّ
WO2016172551A8 (en) METHODS OF IDENTIFYING BACTERIA COMPRISING BINDING POLYPEPTIDES
MX2022001896A (es) Formulaciones anti-c5 de alta concentracion.
PH12020550117A1 (en) Variant rnai
MX2019010045A (es) Metodos para determinar la potencia de preparaciones de virus adeno-asociados.
BR112022022644A2 (pt) Composições de vírus adeno-associados compatíveis com espécies cruzadas e método de uso destas
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
EP3989994A4 (en) RECOMBINANT AAV VECTORS WITH ALTERED IMMUNOGENICITY AND METHODS FOR THEIR PRODUCTION
WO2018175740A8 (en) Anti-tmeff1 antibodies and antibody drug conjugates
WO2015057966A3 (en) THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV)
WO2018085551A3 (en) Formulations of pegylated arginine deiminase